Image
![ZENEO auto-injecteur](/sites/default/files/2024-07/ZENEO_Autoinjecteur%20sans%20aiguille2_2.jpg)
Date de parution
Sommaire ou résumé
Dijon, France, July 15th 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO®, announces it will attend the H.C. Wainwright 26th Annual Global Investment Conference, taking place in New York September 9-11, 2024.
PDF du document
PR_HCW_v1.pdf146.43 KB